Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline-Reference-Cited by-同舟云学术

Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline

Published:2019-02-14 Issue:3 Volume:21 Page:386-388
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Januzzi James¹,Ferreira João Pedro²³⁴,Böhm Michael⁵,Kaul Sanjay⁶,Wanner Christoph⁷,Brueckmann Martina⁸⁹,Petrie Mark C.¹⁰,Ofstad Anne Pernille¹¹,Zeller Cordula¹²,George Jyothis⁸,Fitchett David¹³,Zannad Faiez²³⁴

Affiliation:

1. Cardiology DivisionMassachusetts General Hospital, Baim Institute for Clinical Research Boston MA USA

2. Centre d'Investigations Cliniques Plurithématique Inserm 1433Université de Lorraine Nancy France

3. CHRU de Nancy, Inserm U1116Université de Lorraine Nancy France

4. FCRIN INI‐CRCTUniversité de Lorraine Nancy France

5. Universität des Saarlandes, Klinik für Innere Medizin III, Kardiologie, Angiologie und internistische Intensivmedizin Homburg Germany

6. Division of CardiologyCedars‐Sinai Medical Center Los Angeles CA USA

7. Division of NephrologyWurzburg University Clinic Wurzburg Germany

8. Boehringer Ingelheim International GmbH Ingelheim Germany

9. Faculty of Medicine MannheimUniversity of Heidelberg Mannheim Germany

10. Department of Cardiology, Institute of Cardiovascular and Medical SciencesUniversity of Glasgow Glasgow UK

11. Boehringer Ingelheim Norway KS Asker Norway

12. Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany

13. Division of Cardiology, St Michael's HospitalUniversity of Toronto Toronto Canada

Funder

Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.1419

Reference7 articles.

1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

2. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

3. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

4. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus

5. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study;Open Heart;2022-05

2. Egyptian expert opinion for the use of sodium‐glucose cotransporter‐2 inhibitors in patients with heart failure with reduced ejection fraction;ESC Heart Failure;2022-02-03

3. Sodium-Glukose-Transporter 2(SGLT2)-Hemmer bei Herzinsuffizienz;Der Kardiologe;2022-01-28

4. SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?;Current Heart Failure Reports;2021-09-15

5. Chinese Guideline on the Primary Prevention of Cardiovascular Disease;Cardiology Discovery;2021-07-08